Pd-l1 expression on circulating tumor cells can be a predictive biomarker to pd-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma

HIGHLIGHTS

• who: Ke Su from the University of Bologna, Italy have published the paper: PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma, in the Journal: (JOURNAL) of October/30,/2021
• what: The authors aimed to confirm whether PD-L1+ CTCs could be a predictive biomarker in HCC patients treated with triple therapy. The authors performed multiple assessments on the PDL1 expression on CTCs of HCC patients treated with triple therapy using the CytoSorter ™ BioScanner system. Although patients in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.